REGÍSTRESE

Donar

Iniciar sesión

The CRI Anna-Maria Kellen Clinical Accelerator

¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.

Copy Link

Overview

Components

Clinical Trials

Press

$127 Million Invested

19 Trials Supported

850+ Patients Treated

65+ Articles Published

The CRI Anna-Maria Kellen Clinical Accelerator is a unique nonprofit-academia-industry collaboration model that serves as an “incubator” for multi-center clinical trials testing promising new cancer immunotherapy combinations. As the Cancer Research Institute (CRI)’s clinical program, it enables integrative science-driven collaborative clinical research platforms to de-risk cancer immunotherapy drug development in a manner that leverage’s CRI philanthropic venture funding of clinical studies.

Clinical Accelerator Components

The CRI Anna-Maria Kellen Clinical Accelerator, supported by CRI’s venture philanthropy fund, fosters a cooperative environment that enables leading academic researchers to advance their most ambitious ideas into clinical development. In addition, it accelerates clinical studies that no one group or pharmaceutical company could do alone, bringing promising new treatment options to cancer patients.

Venture Fund

CRI VENTURE PHILANTHROPY FUND

Philanthropic dollars fuel the CRI Venture Fund, which deploys capital to accelerate the creation and execution of innovative immunotherapy clinical trials that aim to improve clinical outcomes for cancer patients.

The CRI Venture Fund realizes returns on its invested capital based on the clinical and regulatory development of the therapeutics it financially supports. Milestone payments (returns) are based on predetermined clinical and regulatory triggers. Earned milestone payments are then available to support future clinical studies through the CRI Venture Fund.

Research Network

GLOBAL CLINICAL RESEARCH NETWORK

The CRI Clinical Accelerator research network includes more than 90 of the world’s leading physician-scientists who have expertise in diverse clinical practices, cancer immunotherapy clinical trials, and immune monitoring. CRI’s leadership position in advancing cancer immunologyresearch for more than 65 years has yielded deep relationships with a global network of scientists, clinicians, and research institutions. Based on their areas of expertise, our researchers are organized into different focus groups, called drug selection committees. These committees propose science-based, biologically driven immunotherapy combinations to be studied in our clinical trials. These proposals are prioritized by the Clinical Accelerator leadership team, financed by our Venture Philanthropy Fund, and made possible through our robust relationships with academia and industry.

Meet Our Investigators

IO Landscape

IMMUNO-ONCOLOGY LANDSCAPE ANALYSES

The CRI Clinical Accelerator immuno-oncology landscape analyses present unbiased, scientifically curated, and routinely updated overviews of new investigational I-O agents and cancer immunotherapy clinical trials. These analyses allow the Clinical Accelerator to identify opportunities where the testing of novel immunotherapy combinations can generate the most impact. Thus, CRI is better able to support our global research network in creating rational, non-duplicative clinical trials. The results of our analyses are made available to the public on our website in addition to publication in peer-reviewed scientific journals.

View Our Landscape

Centralized Access

Centralized Access to Therapies

The CRI Clinical Accelerator team actively monitors the rapidly evolving cancer immunotherapy landscape and works directly with industry and nonprofit organizations to source innovative agents for evaluation in our clinical trials. These strategic partnerships have enabled access to more than 40 different clinical-stage agents to date. Our drug selection committees propose how combinations of these agents should be studied in the clinic by members of our global research network. Such combinations include checkpoint inhibitors, therapeutic vaccines, immunomodulators, oncolytic viruses, and many other promising treatments and technologies with high therapeutic potential.

Leadership

CLINICAL ACCELERATOR LEADERSHIP

The Clinical and Scientific Advisory Committee guides the clinical vision, strategy, and studies of the Clinical Accelerator. The management team is composed of highly experienced professionals with relevant experience in immunology, business development, regulatory sponsorship, clinical trial management, and data analysis and reporting. This team works closely with members of the scientific leadership in developing, implementing, and executing CRI-sponsored clinical trials.

Meet Our Leadership

Partnerships

Nonprofit and Academic Partnerships

The CRI Clinical Accelerator leverages relationships with nonprofits and companies to fund and deliver multi-center studies that could not be accomplished alone. Through these global partnerships, we advance ambitious clinical and translational research aimed at expanding the benefits of immunotherapy to more patients and, ultimately, curing cancer. Our partners provide key support to the program by contributing strategic direction and managing the logistical operations of our trials. They also provide critical funding and/or access to emerging technologies and therapeutic agents. The CRI Clinical Accelerator is proud to be supported by these outstanding organizations and welcomes new partnerships to de-risk novel combination strategies in immuno-oncology.

Meet Our Partners

Clinical Accelerator Trials

The CRI Anna-Maria Kellen Clinical Accelerator aims to reduce inefficiencies and duplicative efforts by building multi-site, multi-company platform trials with deep translational and correlative science to advance immunotherapy. Below are clinical trials supported by the Clinical Accelerator as of February 2021.

Clinical Trials - Enrolling

ILIAD-7-US-O-InterLeukin-7 to improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection (NCT04426201)

Anne Rain Brown, PharmD, MD Anderson Cancer Center
Cassian Yee, M.D., MD Anderson Cancer Center
Cristina Gutierrez, M.D., MD Anderson Cancer Center (Study chair)
John Cuenca, M.D., MD Anderson Cancer Center
Joseph Nates, M.D., MD Anderson Cancer Center
Marcel van den Brink, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Mayoora Muthu, D.O., MD Anderson Cancer Center
Stephen M. Pastores, M.D., Memorial Sloan Kettering Cancer Center (Study chair)

Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with NSCLC (NCT04093167)

Adrian Sacher, M.D., Princess Margaret Cancer Centre
Andrea Fung, M.D., Ph.D., Kingston Health Sciences Centre
Cheryl Ho, M.D., Vancouver Cancer Centre (Study chair)
Garth Nicholas, M.D., The Ottawa Hospital Research Institute
Peter Ellis, M.D., Juravinski Cancer Centre at Hamilton Health Sciences
Valsamo (Elsa) Anagnostou, M.D., Johns Hopkins University (Study chair)

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) (NCT03835533)

Charles Drake M.D., Ph.D., Columbia University
Julie Graff, M.D., Oregon Health & Science University
Karen Autio, M.D., Memorial Sloan Kettering Cancer Center
Kristopher Weintzel, M.D., Angeles Clinic
Larry Fong, M.D., University of California, San Francisco
Matt Galsky, M.D., Mount Sinai
Sumit Subhudhi, M.D., Ph.D., MD Anderson Cancer Center (Study chair)

Treatment with Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (NCT03651271)

Alexandra Drakaki, M.D., Ph.D., University of California, Los Angeles
Apostolia Tsimberidou, M.D., Ph.D., MD Anderson Cancer Center
Danny Khalil, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
David Oh, M.D., Ph.D., University of California, San Francisco
Padmanee Sharma, M.D., Ph.D., MD Anderson Cancer Center (Study chair)
Saad Khan, M.D., Stanford University
Stephen Hodi, M.D., Dana Farber Cancer Institute

A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers (NCT02643303)

Craig Slingluff Jr., M.D., University of Virginia Health (Study chair)
Danae Hamouda, M.D., Toledo University
Elizabeth Gaughan, M.D., University of Virginia Health
Igor Puzanov, M.D., Roswell Park Cancer Institute
Keisuke Shirai M.D., Dartmouth University
Megan Kruse, M.D., Cleveland Clinic
Michael Lowe, M.D., Emory University
Nina Bhardwaj, M.D., Ph.D., Mount Sinai (Study chair)

Results

Slingluff CL, Dasilva D, Schwarzenberger P, et al. Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors. Journal of Clinical Oncology. 2018.
Slingluff CL, et al. Abstract #P246 presented at SITC 2017 Annual Meeting (November 8-12, 2017).

Clinical Trials - Enrollment Complete

A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-Tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects with Advanced Peritoneal Malignancies (NCT02963831)

Augustin Pimental, M.D., University of Miami
Danae Hamouda, M.D., University of Toledo
Dmitriy Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
Emese Zsiros, M.D., Roswell Park Cancer Institute
Hitendra Patel, M.D., University of California, San Diego
Linda Duska, M.D., University of Virginia Health

Results

Zamarin D, et al. Abstract presented at the 2020 ASCO Virtual Scientific Program (May 29-31, 2020).

Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with NSCLC (NCT03164772)

Hirva Mamdani, M.D., Karmanos Cancer Institute
Jhanelle Gray, M.D., Moffitt Cancer Center (Study chair)
Jiaxin Niu, M.D., Banner MD Anderson
Jonathan Thompson, M.D., Medical College of Wisconsin
Joshua Sabari, M.D., NYU Langone

Safety and Efficacy of APX005M with Gemcitabine and Nab-Paclitaxel with or without Nivolumab in Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (NCT03214250)

Andrew Ko, M.D., University of California, San Francisco
Eileen O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
George Ficher, M.D., Stanford University
Mark O’Hara, M.D., University of Pennsylvania
Osama Rahma, M.D., Dana-Farber Cancer Institute
Robert Vonderheide, M.D., D.Phil., University of Pennsylvania (Study chair)
Robert Wolff, M.D., MD Anderson Cancer Center
Zev Wainberg, M.D., University of California, Los Angeles

Results

O'Hara M, O'Reilly E, Varadhachary G et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology. 2021.
O'Hara M, O'Reilly E, Rosemarie M et al. Abstract CT004. A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Clinical Trials. 2019. (Abstract presented at AACR Annual Meeting 2019, March 29, 2019, by Mark O'Hara.)

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer (NCT02431559)

Blanca Navarro, M.D., University Hospital of Lausanne, Lausanne, Switzerland
Bradley Monk, M.D., Arizona Oncology
David O’Malley, M.D., Ohio State University
George Coukos, M.D., Ph.D., University Hospital of Lausanne, Lausanne, Switzerland (Study chair)
Paul DiSilvestro, M.D., Woman and Infants Hospital
Roisin O’Cearbhail, M.D., Memorial Sloan Kettering Cancer Center

Results

Orcurto A, et al. Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer. Clinical Oncology: Case Report, Vol: 4 Issue: 3, March 10, 2021.
O'Cearbhaill R.E., et al. Abstract presented at the Society of Gynecologic Oncology (SGO) 2020 Annual Meeting on Women’s Cancer Webinar Series: Developmental Therapeutics in Gynecological Cancer Webinar. May 28, 2020.
O'Cearbhaill R.E., Wolfer A. et al. A phase 1/2 study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian... Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. (Abstract presented at ESMO 2018 Congress, Poster display session, 20 October 2018, by Roisin O'Cearbhaill.)

Phase 2 Study of Durvalumab (MEDI4736) in Patients with Glioblastoma (NCT02336165)

David Reardon, M.D., Dana-Farber Cancer Institute (Study chair)
Gavin Dunn, M.D., Ph.D., Washington University, St Louis
Hui Gan, M.D., Austin Hospital, Australia
Jennifer Clarke, M.D., M.P.H., University of California, San Francisco
Jorg Dietrich, M.D., Mass General Hospital
Michael Lim, M.D., Johns Hopkins
Thomas Kaley, M.D., Memorial Sloan Kettering Cancer Center
Tim Cloughesy, M.D., University of California, Los Angeles

Results

Reardon DA, Kaley TJ, Dietrich J, et al. Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). Journal of Clinical Oncology. 2019.
Reardon D, Kaley T, Dietrich J, et al. ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2018;20(suppl_6):vi10-vi10.
Reardon D, Kaley T, Dietrich J, et al. ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM). Neuro-Oncology. November 2017;19(suppl_6):vi28-vi28.
Casey Allie. Checkpoint Inhibitors Show Promise in Glioblastoma. OncLive.com. Published: Friday, Nov 18, 2016.

A Phase 1 Study to Evaluate MEDI4736 in Combination with Tremelimumab (NCT01975831)

Antoni Ribas, M.D., Ph.D., University of California, Los Angeles
Jedd Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
Kunle Odunsi, M.D., UChicago Medicine Comprehensive Cancer Center
Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center (Study chair)
Mario Sznol, M.D., Yale University
Patrick Dillon M.D., University Virginia Health
Patrick Ott, M.D., Dana-Farber Cancer Institute
Reva Schneider, M.D., Mary Crowley Cancer Center

Results

Callahan MK, Odunsi K, Sznol M, et al. Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. Journal of Clinical Oncology. 2018.

Clinical Trials - Completed

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001) (NCT01239134)

Henry Koon, M.D., University Hospitals
Dale Shepard, M.D., Ph.D., Cleveland Clinic
Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Results

Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. 2019. Rational design of anti-GITR-based combination immunotherapy.
Koon HB, Shepard DR, Merghoub T, Schaer DA, Sirard CA, Wolchok JD. First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors. Journal of Clinical Oncology. 2018.

Trials Supported with Reagents

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58) (NCT01585350)

Craig L. Slingluff Jr., M.D., University of Virginia Health System

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer (NCT02015416)

Immune Design, Seattle, WA

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers (NCT00291473)

Hiroshi Shiku, M.D., and Shinichi Kageyama, M.D., Mie University School of Medicine, Mie, Japan

A phase I study of concomitant WT1 analog peptide and NY-ESO-1

David O’Malley, M.D., The Ohio State University Wexner Medical Center
Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center

A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1

Yuichiro Doki, Ph.D., and Hisashi Wada, M.D., Ph.D., Osaka University, Japan

A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/lymphoma expressing NY-ESO-1

Yuzuru Kanakura, Ph.D., and Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Japan

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence (NCT02334735)

Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) (NCT01532960)

Catherine M. Diefenbach, M.D., NYU Langone Medical Center

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in stage IB-IIIA breast cancer

Patrick M. Dillon, M.D., University of Virginia Health System

A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21

Samuel Danishefsky, Ph.D., Memorial Sloan Kettering Cancer Center

Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma (Mel63; CHAMP) (NCT02425306)

Craig L. Slingluff Jr., M.D., University of Virginia Health System

Results

Singluff CL, Zarour HM, Tawbi HA, et al. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. 2021.

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59) (NCT01846143)

Victor H. Engelhard, Ph.D., and Craig L. Slingluff Jr., M.D., University of Virginia Health System

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients (NCT01079741)

Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai

Phase I/II trial of a long peptide vaccine (LPV8) + Toll-like receptor agonists for resected stage IIB-IV

Craig L. Slingluff Jr., M.D., University of Virginia Health System

Role of Toll-like receptor 3 in macrophage-mediated programmed cell removal of tumor cells

Irving Weissman, M.D., Stanford University School of Medicine

Safety and immunogenicity of vaccination with XAGE1b long peptides combined with Poly-ICLC in patients with stage III/IV pulmonary adenocarcinoma

Christian Taube, M.D., and Maarten L. Zandvliet, Ph.D., Leiden University Medical Center, The Netherlands

Terminated

Nivolumab Ipilimumab in Patients with HyperMutated Cancers Detected in BLood (NIMBLe) (NCT03461952)

Early termination due to low enrollment

Naiyer Rizvi, M.D., Ph.D., Herbert Irving Comprehensive Cancer Center, Columbia University
Stephen Chia, M.D., British Columbia Cancer Agency, Canada
Holger Hirte, M.D., Juravinski Cancer Center, Canada
Patricia Tang, M.D., Tom Baker Cancer Center, Canada
Michael Vickers, M.D., MPH, The Ottawa Hospital, Canada

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer (NCT02898116)

Early termination due to the rapidly changing treatment landscape for ALK-positive NSCLC, resulting in low enrollment

Leena Gandhi, M.D., Ph.D., NYU Langone's Perlmutter Cancer Center

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant (NCT02716805)

FDA placed on partial hold due to additional data

Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center

Clinical Accelerator Press

The CRI Anna-Maria Kellen Clinical Accelerator team and affiliated scientists publish our new developments and contributions in the field of immunotherapy in prestigious journals, blog posts, and press releases.

Press Releases

Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy Trials
CRI Press Release, February 10, 2022
Cancer Research Institute and RevImmune Announce Dosing of First Patient in New Phase 2 Study Assessing Therapeutic Benefit of Interleukin-7 in Patients with Cancer and COVID-19
CRI Press Release, March 30, 2021
Combination Drug Strategies Gain Ground in Global Immuno-Oncology Pipeline of PD-1 and PD-L1 Clinical Trials
CRI Press Release, November 11, 2020
An Initative Led by Parker Institute for Cancer Immunotherapy and Cancer Research Institute Discovers Keys That Could Unlock Better Personalized Treatments to Destroy Cancer
CRI Press Release, October 9, 2020
I mmunotherapy Drug Development Pipeline Continues Significant Growth In 2020 Despite Global Pandemic Impact
CRI Press Release, September 18, 2020
Cancer Research Institute and the Mark Foundation for Cancer Research Launch Research Collaboration to Evaluate Liquid Biopsy for More Accurate and Rapid Assessment of Lung Cancer Patient Response to Immunotherapy
CRI Press Release, July 22, 2020
Rapid Growth in Global Development of Cancer Cellular Immunotherapies Highlighted by Latest Report from Cancer Research Institute and GlobalData
CRI Press Release, May 26, 2020
Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials
CRI Press Release, May 18, 2020
Latest Global Immuno-Oncology Landscape Report from the Cancer Research Institute Published in Nature Reviews Drug Discovery
CRI Press Release, September 27, 2019
New Report Charts Dramatic Growth in the Global Clinical Trial Landscape for PD-1/L1 Immune Checkpoint Inhibitors
CRI Press Release, November 28, 2018
New International Research Collaboration Explores Blood-Based Biomarker Testing to Identify Cancer Patients that Could Potentially Respond to Immunotherapy
CRI Press Release, October 2, 2018
Foundation for the National Institutes of Health and Cancer Research Institute Announce New Collaboration in Cancer Immunotherapy
CRI Press Release, July 30, 2018
Ludwig Cancer Research and Cancer Research Institute Launch Clinical Trial Combining Virotherapy and Immunotherapy to Treat Advanced Colorectal and Ovarian Cancers
CRI Press Release, July 11, 2018
New Report on the Global Landscape of Cancer Cell Therapy Highlights Robust International Pipeline Marked by Rapid Growth
CRI Press Release, May 25, 2018
Cancer Research Institute and Canadian Cancer Trials Group Announce Strategic Collaboration
CRI Press Release, January 8, 2018
The Cancer Research Institute Announces Publication of Comprehensive Immuno-Oncology Landscape Analysis in Annals of Oncology
CRI Press Release, December 7, 2017
The Cancer Research Institute and Parker Institute for Cancer Immunotherapy Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy
CRI Press Release, September 20, 2017
Immunotherapy Data from CRI Clinical Accelerator to Be Presented at ASCO Annual Meeting
CRI Press Release, May 23, 2017
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and the Cancer Research Institute Announce Collaboration to Accelerate Immuno-Oncology Research
CRI Press Release, March 28, 2017
Cancer Research Institute Awards Grant to Develop Powerful Genomic Data Resource for Cancer Immunotherapy Researchers
CRI Press Release, January 31, 2017
Ludwig Cancer Research and the Cancer Research Institute Initiate Clinical Trial of a Novel Combination Immunotherapy For Ovarian Cancer
CRI Press Release, April 6, 2016
Cancer Research Institute and Ludwig Cancer Research Partner with Targovax to Test Candidate Virotherapy in Early-Phase Clinical Trials
CRI Press Release, November 18, 2015
Ludwig Cancer Research and the Cancer Research Institute Evaluate Immunotherapeutic Strategies for Brain Cancer and Other Types of Solid Tumors
CRI Press Release, July 8, 2015
Ludwig Cancer Research and Cancer Research Institute Collaborate on Evaluation of VentiRx's Investigational Immunotherapy
CRI Press Release, September 3, 2014

Publications

Landscape of cancer cell therapies: trends and real-world data
Nature Reviews Drug Discovery, June 1, 2022
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape
Nature Reviews Drug Discovery, February 10, 2022
The clinical pipeline for cancer cell therapies
Nature Reviews Drug Discovery, June 4, 2021
COVID-19 impact on oncology clinical trials: a 1-year analysis
Nature Reviews Drug Discovery, May 17, 2021
Successful Treatment with Rituximab of Sjögren’s Syndrome-Associated Organizing Pneumonia in a Patient Treated with PD-L1 Blockade for Ovarian Cancer
Clinical Oncology: Case Report, March 10, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
The Lancet Oncology, January 1, 2021
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials
Nature Reviews Drug Discovery, November 11, 2020
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Cell, October 9, 2020
Immuno-oncology drug development forges on despite COVID-19
Nature Reviews Drug Discovery, September 18, 2020
Cancer cell therapies: the clinical trial landscape
Nature Reviews Drug Discovery, May 26, 2020
Impact of COVID-19 on oncology clinical trials
Nature Reviews Drug Discovery, May 18, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
Journal for ImmunoTherapy of Cancer, April 1, 2020
Trends in clinical development of PD-1/PD-L1 inhibitors
Nature Reviews Drug Discovery, November 4, 2019
Immuno-Oncology Drug Development Goes Global
Nature Reviews Drug Discovery, September 27, 2019
The global pipeline of cell therapies for cancer
Nature Reviews Drug Discovery, May 30, 2019
Immunotherapy and targeted therapy combinations in metastatic breast cancer
The Lancet Oncology, March 2019
The clinical trial landscape for PD1/L1 immune checkpoint inhibitors
Nature Reviews Drug Discovery, November 28, 2018
Trends in the global immuno-oncology landscape
Nature Reviews Drug Discovery, October 19, 2018
Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies
Annals of Oncology, September 10, 2018
The global landscape of cancer cell therapy
Nature Reviews Drug Discovery, May 25, 2018
Comprehensive analysis of the clinical immuno-oncology landscape
Annals of Oncology, January 1, 2018
A Blueprint to Advance Colorectal Cancer Immunotherapies
Cancer Immunology Research, November 2017
Translating Science into Survival: Report on the Second International Cancer Immunotherapy Conference
Cancer Immunology Research, December 2016
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute
Cancer Immunology Research, April 2016
Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference
Cancer Immunology Research, January 2016
T cell assays and MIATA: the essential minimum for maximum impact
Immunity, July 27, 2012
The Cancer vaccine Collaborative: a new model of coordinated discovery
Cancer Immunology Research, 2012
A methodological framework to enhance the clinical success of cancer immunotherapy
Nature Biotechnology, October 13, 2011
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond
Cancer Immunology Immunotherapy, January 2011

Media Mentions

COVID’s impact on cancer therapeutics: clinical trial and treatment disruptions
European Pharmaceutical Review, February 19, 2021
How COVID-19 Has Impacted Oncology Trials
Healthcare Tech Outlook, February 11, 2021
Oncology Centers Examine the Aftermath of COVID-19 on Clinical Trials
OncLive, June 19, 2020
Hospitals Are Bracing For a Spike in Cancer Patients as Covid Ebbs
Bloomberg, June 11, 2020
COVID-19 slows sign-ups for clinical cancer trials
Becker's Hospital Review, May 27, 2020
IQVIA & Cancer Research Institute Study Reveals Devastating Impact of COVID-19 on Oncology Clinical Trials
Trial Site News, May 24, 2020
More Than 200 International Cancer Trials Suspended Due to COVID-19
Medscape, May 22, 2020
Changes to Global Oncology Trial Management Due to COVID-19
Cancer Network, May 20, 2020
Biopharma Update on the Novel Coronavirus: May 18
BioSpace, May 18, 2020
Can Innate Immune Cells Engage in Anti-Tumor Activity?
OBR, May 2020
Inovio's Wild Ride And Real Value
SeekingAlpha, March 25, 2020
All chips on immuno-oncology is not a good gamble
BioCentury, January 13, 2020
Takeda sees cell, gene therapy in its future. Is it too late?
BioPharma Dive, November 20, 2019
Immuno-oncology Boom Doubles Drugs in Development in 2 Years
Cancer Network, October 11, 2019
How Technology Is Helping Revolutionize Cancer Treatment
Forbes, October 4, 2019
Cancer immunotherapy boom showing no sign of slowdown
BioPharma Dive, September 27, 2019
Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials
STAT, September 4, 2019
Immunotherapy: Combine and Conquer
Nature Medicine, May 7, 2015
CRI and Cancer Immunology
CenterWatch, April 27, 2015
Fresh funds in hand, VentriRx joins AstraZeneca, Ludwig and CRI for combo immuno-oncology study
Fierce Biotech, September 3, 2014

Blog Articles

Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
CRI Blog, April 8, 2020
CRI-Sponsored Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
CRI Blog, March 31, 2019
Advocating for Innovative Clinical Trial Design
CRI Blog, April 25, 2018
Immunotherapy in the Fast Lane: CRI's Clinical Accelerator Takes Off
CRI Blog, January 7, 2014

*Los resultados de la inmunoterapia pueden variar de un paciente a otro.

Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111

800-992-2623 212-832-9376 Directorio de Personal

Reciba noticias del CRI

Síganos

Entradas recientes del blog

Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.

Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).

Top